The Doris Duke Sickle Cell Disease/Advancing Cures Award
The Doris Duke Sickle Cell Disease/Advancing Cures award provides grants to advance curative approaches for sickle cell disease including, gene modification and drug therapies to restore hemoglobin function.
Research over the past five decades has resulted in treatments for sickle cell disease treatments that have decreased childhood mortality and improved patients’ disease management options for patients with sickle cell disease. However, further efforts are needed to develop approaches that aim to attack the disease at its core by safely and sustainably restoring hemoglobin function. The Sickle Cell Disease/Advancing Cures award was created to harness promising scientific advances toward restoring hemoglobin function and enable their development into clinically feasible therapies and ultimately practical use.
The foundation seeks to support about eight, three-year research projects through Sickle Cell Disease/Advancing Cures awards. Flexible, annual direct-cost amounts of $150,000 to $300,000 will be considered, plus a 10 percent annual indirect cost allowance. This program aims to support clinical research that will:
Advance gene therapies for sickle cell disease into the clinic, including gene addition and genome editing.
Build on globin regulatory mechanisms to restore red blood cell function.
For details, view the Request for Applications & Application Instructions here.
In keeping with the wishes expressed in Doris Duke's will, experiments that use animals or primary tissues derived from animals will not be supported by this program.
Full proposals due May 25, 2017, 3 pm ET